The primary finding of this study is that EGCG may be an effective agent for preventing aging-related CDD and cTnI expression decline by inhibiting HDAC1 and increasing AcH3 and AcH3K9 near cTnI's promoter in aged mice (Fig. 6). This evidence concerns the gene TNNI3 and craniodiaphyseal dysplasia.